Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

Medicine & Life Sciences

• Mineralocorticoids 100%
• Spironolactone 98%
• Angiotensin Receptors 95%
• Losartan 93%
• Peptidyl-Dipeptidase A 85%
• Diabetic Nephropathies 82%
• Creatinine 61%
• Albumins 49%
• Urine 41%
• Placebos 40%
• Lisinopril 27%
• Mineralocorticoid Receptor Antagonists 25%
• Albuminuria 22%
• Angiotensin Receptor Antagonists 21%
• Sclerosis 20%
• Aldosterone 20%
• Angiotensin-Converting Enzyme Inhibitors 19%
• Electrolytes 18%
• Angiotensin II 18%
• Urea 18%
• Potassium 17%
• Renal Insufficiency 17%
• Sodium 16%
• Animal Models 13%
• Hypertension 12%
• Serum 8%
• Proteins 7%